Dr. Jeffrey Infante on the Positive Results of Using Avelumab in Patients With Ovarian Cancer
November 10th 2015Jeffrey R. Infante, MD director of Drug Development, Sarah Cannon Research Institute, talks about the anti-PD-L1 antibody avelumab in patients with previously treated, recurrent or refractory ovarian cancer.